Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Ferro

Showing results (391-400 of 420) with videos related to

Pageof 42
Sort By:
Urologic Oncology|February 1, 2024
Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional databaseAnnamaria Porreca, Marta Di Nicola, Giuseppe Lucarelli, et al.
BJU International|September 12, 2024
Robot-assisted nephroureterectomy: surgical and mid-term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group)Francesco Ditonno, Antonio Franco, Zhenjie Wu, et al.
Minerva Urology and Nephrology|January 13, 2021
Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter studyMatteo Ferro, Michele Marchioni, Giuseppe Lucarelli, et al.
Minerva Urology and Nephrology|April 4, 2025
A pretreatment nomogram to predict muscle-invasiveness in high-risk upper tract urothelial carcinoma (ROBUUST 2.0 collaborative group)Francesco Ditonno, Antonio Franco, Eugenio Bologna, et al.
Cancers|April 13, 2023
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-AnalysisFrancesco Del Giudice, Vincenzo Asero, Eugenio Bologna, et al.
Clinical Genitourinary Cancer|September 4, 2023
Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial CarcinomaMatteo Ferro, Sever Chiujdea, Mihai Dorin Vartolomei, et al.
Frontiers in Oncology|May 23, 2022
Robot-Assisted, Laparoscopic, and Open Radical Cystectomy: Pre-Operative Data of 1400 Patients From The Italian Radical Cystectomy RegistryGian Maria Busetto, Daniele D'Agostino, Michele Colicchia, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world multicenter adherence to international guidelines in the management of upper tract urothelial carcinoma: insights from the ROBUUST 2.0 RegistryMariaconsiglia Ferriero, Gabriele Tuderti, Flavia Proietti, et al.
Frontiers in Oncology|May 28, 2021
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional AnalysisMatteo Ferro, Ottavio de Cobelli, Gennaro Musi, et al.
Future Science OA|July 14, 2021
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomyMatteo Ferro, Dragoş-Florin Babă, Ottavio de Cobelli, et al.
Pageof 42

Showing results (391-400 of 420) with videos related to

Sort By:
Pageof 42
Urologic Oncology|February 1, 2024
Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional databaseAnnamaria Porreca, Marta Di Nicola, Giuseppe Lucarelli, et al.
BJU International|September 12, 2024
Robot-assisted nephroureterectomy: surgical and mid-term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group)Francesco Ditonno, Antonio Franco, Zhenjie Wu, et al.
Minerva Urology and Nephrology|January 13, 2021
Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter studyMatteo Ferro, Michele Marchioni, Giuseppe Lucarelli, et al.
Minerva Urology and Nephrology|April 4, 2025
A pretreatment nomogram to predict muscle-invasiveness in high-risk upper tract urothelial carcinoma (ROBUUST 2.0 collaborative group)Francesco Ditonno, Antonio Franco, Eugenio Bologna, et al.
Cancers|April 13, 2023
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-AnalysisFrancesco Del Giudice, Vincenzo Asero, Eugenio Bologna, et al.
Clinical Genitourinary Cancer|September 4, 2023
Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial CarcinomaMatteo Ferro, Sever Chiujdea, Mihai Dorin Vartolomei, et al.
Frontiers in Oncology|May 23, 2022
Robot-Assisted, Laparoscopic, and Open Radical Cystectomy: Pre-Operative Data of 1400 Patients From The Italian Radical Cystectomy RegistryGian Maria Busetto, Daniele D'Agostino, Michele Colicchia, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world multicenter adherence to international guidelines in the management of upper tract urothelial carcinoma: insights from the ROBUUST 2.0 RegistryMariaconsiglia Ferriero, Gabriele Tuderti, Flavia Proietti, et al.
Frontiers in Oncology|May 28, 2021
Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional AnalysisMatteo Ferro, Ottavio de Cobelli, Gennaro Musi, et al.
Future Science OA|July 14, 2021
Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomyMatteo Ferro, Dragoş-Florin Babă, Ottavio de Cobelli, et al.
Pageof 42